Aumentare lo sviluppo industriale delle vescicole extracellulari (EVs) CD99-null come strumento terapeutico utilizzando il sarcoma di Ewing come prototipo

Title

Code

START

Type

Sperimentale

Start Year

2024

Status

In Corso

Principal Investigator

051-6366652

marco.gambarotti@ior.it

Gambarotti Marco, MD

Head

Anatomy and Pathological Histology

Operational unit that carry out the study

departmental simple unit

Anatomia e istologia patologica

Head

Gambarotti Marco, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. START

Monday 18 March 2024, 13:46

PG0004318_2024_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

Sito Web Istituto Ortopedico Rizzoli

DIPARTIMENTO RIZZOLI-SICILIA

Aumentare lo sviluppo industriale delle vescicole extracellulari (EVs) CD99-null come strumento terapeutico utilizzando il sarcoma di Ewing come prototipo

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in